Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies
Journal of Clinical Medicine · 20.03.2024 · 13 (6) · 1781
DOI: 10.3390/jcm13061781 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.03.2024. Verfasst von Abhinav Aggarwal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe hereditary arrhythmia syndrome predominantly affecting children and young adults. It manifests through bidirectional or polymorphic ventricular arrhythmia, often culminating in syncope triggered by physical exertion or emotional stress which can lead to sudden cardiac death. Most cases stem from mutations in the gene responsible for encoding the cardiac ryanodine receptor (RyR2), or in the Calsequestrin 2 gene (CASQ2), disrupting the handling of calcium ions within the cardiac myocyte sarcoplasmic reticulum. Diagnosing CPVT typically involves unmasking the arrhythmia through exercise stress testing. This diagnosis emerges in the absence of structural heart disease by cardiac imaging and with a normal baseline electrocardiogram. Traditional first-line treatment primarily involves β-blocker therapy, significantly reducing CPVT-associated mortality. Adjunctive therapies such as moderate exercise training, flecainide, left cardiac sympathetic denervation and implantable cardioverter-defibrillators have been utilized with reasonable success. However, the spectrum of options for managing CPVT has expanded over time, demonstrating decreased rates of arrhythmic events. Furthermore, ongoing research into potential new therapies including gene therapies has the potential to further enhance treatment paradigms. This review aims to succinctly encapsulate the contemporary understanding of the clinical characteristics, diagnostic approach, established therapeutic interventions and the promising future directions in managing CPVT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA.
- Division of Cardiology, Department of Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, CT 06605, USA.
- Department of Internal Medicine, Nuvance Health, Norwalk Hospital, Norwalk, CT 06856, USA.
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06519, USA.
ORCID-Profile: Abhinav Aggarwal, Anton Stolear
Zitieren
APA
Aggarwal, A., Stolear, A., Alam, M. M., Vardhan, S., Dulgher, M., Jang, S. J., & Zarich, S. W. (2024). Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies. Journal of Clinical Medicine, 13(6), 1781. https://doi.org/10.3390/jcm13061781
Vancouver
Aggarwal A, Stolear A, Alam MM, Vardhan S, Dulgher M, Jang SJ, et al. Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies. Journal of Clinical Medicine. 2024;13(6):1781. doi:10.3390/jcm13061781
BibTeX
@article{Aggarwal2024,
author = {Aggarwal, Abhinav and Stolear, Anton and Alam, Md Mashiul and Vardhan, Swarnima and Dulgher, Maxim and Jang, Sun-Joo and Zarich, Stuart W},
title = {Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {6},
pages = {1781},
doi = {10.3390/jcm13061781}
}
EUVIMED